FibroGen Inc at Goldman Sachs Healthcare Conference Transcript
I'm Paul Choi, and I cover the small and mid-cap biotechnology sector here at Goldman Sachs. It's my pleasure to welcome Enrique Conterno, CEO of FibroGen. We'll do a little Q&A with Enrique here. The team -- management team is also available here in the audience. If along the way, if anybody in the audience has a question, please feel free to raise your hand, and we'll try and get a mic to you. Also, if you want to ask a question anonymously, you can e-mail it to us and we'll read it over the webcast here.
So Enrique, maybe I'll let you start with maybe some high-level comments and just kind of the year ahead for FibroGen. You've had from a mix of good news and bad news earlier this year with regard to the clinical front, but you also obviously have some potentially thesis changing events coming up here ahead. So could you maybe just talk about maybe at a high level, how you're thinking about FibroGen in 2023.
Thank
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
